Clinical Trial Update: Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)

View source ↗

Summary

This clinical trial update examines how delaying initiation of combined antiretroviral therapy (cART) in primary HIV infection affects immune activation markers…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• combined antiretroviral therapy (cART) (combination antiretroviral therapy)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: HIV-infected Patients | Status: COMPLETED